TERT and hepatocellular carcinoma: The data show that rs2853669 is associated with poor recurrence-free survival rates and a significant risk of HCC recurrence in patients with the TERT promoter mutation (Log-rank test, P = 0.02119; hazard ratio = 5.5611, 95% CI = 1.076–28.75, P = 0.0406 for the SMH cohort; and Log-rank test, P = 0.0173; hazard ratio = 4.6639, 95% CI = 1.157–18.8, P = 0.0304 for the KU cohort; Figure 1C, 1D and Supplementary Table 1).